^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | retlirafusp alfa (SHR-1701) (PD-L1 inhibitor, TGF-β R2 kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-ß, for advanced NSCLC with EGFR mutations: Data from a multicenter phase 1 study.
Published date:
05/19/2021
Excerpt:
In the EGFR+ NSCLC cohort, 27 pts were enrolled...4 of the 24 pts who had at least one post-baseline radiographic assessment achieved objective responses, including 3 ongoing confirmed and 1 unconfirmed partial response. ORR was 16.7% (95% CI, 4.7%-37.4%), and disease control rate was 50.0% (95% CI, 29.1%-70.9%)....SHR-1701 monotherapy shows a manageable safety profile and encouraging antitumor activity in advanced EGFR+ NSCLC pts...
DOI:
10.1200/JCO.2021.39.15_suppl.9055
Trial ID:
